Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA7 | P43166 | 3/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965278 | 0.88 | KMT2A (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3559893 | 0.86 | TSHR (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9080647 | 0.85 | GPR35 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16445513 | 0.84 | KMT2A (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13497805 | 0.84 | KMT2A (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6170431 | 0.84 | KMT2A (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16464384 | 0.84 | KMT2A (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL692577 | 0.84 | KMT2A (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1981486 | 0.83 | KMT2A (0.67) | KMT2AALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL223930 | 0.83 | XDH (0.61) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3694840-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | Hoffmann-La Roche AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| CN-111247129-A | Piperazine derivatives as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2020-06-05 | — | — | CN | disclosed |
| WO-2019072785-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2018-10-02 | — | — | US | disclosed |
| CN-106810463-A | Preparation method of oxybuprocaine hydrochloride | 沈阳绿洲制药有限责任公司 | 2017-06-09 | — | — | CN | disclosed |
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2005051934-A1 | ANTITHROMBOTIC COMPOUNDS WITH DUAL FUNCTION | UNIVERSITY OF LJUBLJANA (SI) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051934-A1 | ANTITHROMBOTIC COMPOUNDS WITH DUAL FUNCTION | UNIVERSITY OF LJUBLJANA (SI) | 2005-06-09 | — | — | WO | disclosed |
| US-5843942-A | Aromatic amino ethers as pain relieving agents | ZENECA LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
| US-4789675-A | HYPOTENSIVE, ANTIISCHEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-12-06 | — | — | US | disclosed |
| EP-0233728-A1 | 1,4-Benzoxazine derivatives their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-08-26 | — | — | EP | disclosed |
| US-4307092-A | 1-Oxo-5H-pyrimido[2,1-C]benzoxazine-2-carboxylic acid esters | AYERST MCKENNA & HARRISON, INC. (CA) | 1981-12-22 | — | — | US | disclosed |
| US-4254118-A | 1-Oxo-5H-pyrimido[2,1-c][1,4]benzthiazine-2-carboxylic acid esters | AYERST, MCKENNA & HARRISON INC. (CA) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | FPR1, FFAR1, GLS | CA12 3091/4885CA1 591/4885CA2 369/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | CA12 4418/4885CA1 3979/4885CA2 1231/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | CA12 4418/4885CA1 3979/4885CA2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.